One established biomarker for neuroinflammatory cognitive decline is plasma C-reactive protein (CRP), which is associated with an increased risk of AD (Song et al., 2015; Brosseron et al., 2018), cSVD (Hilal et al., 2018), and PD (Umemura et al., 2015). This evidence concerns the gene CRP and Alzheimer disease.